TRON is delighted to announce a scientific article published in Oncotarget.
We are delighted to announce that TRON scientist Dr. Luisa Bresadola has won the Bristol-Myers-Squibb Young Scientist award in the field of immune-oncology! Luisa’s work comprises analysis of head and neck squamous cell carcinoma next-generation sequencing data, generated by TRON in collaboration with the University of Birmingham, to determine tumor evoluation in this cancer entity.
TRON unterstützt das Anliegen der Landesregierung und tritt gemeinsam mit der Landesregierung für unsere Grundwerte ein. Nur gemeinsam können wir zeigen, dass die Mehrheit für Respekt und gegen Hass steht. „Rheinland-Pfalz ist ein lebenswertes und weltoffenes Land. Das wollen wir auch in Zukunft sein. Deshalb finden wir uns nicht damit ab, dass der Umgang auf
Although chimeric antigen receptor (CAR)-modified T cells (CAR T-cells) have been shown to be effective against hematological malignancies, evidence of their potential against immune-suppressive solid tumors is missing. Key challenges for this include the selection of tumor-specific targets and the persistence of CAR-T cells upon adoptive transfer. In this study, teams from Biontech and TRON
Mainz, December 9, 2019 – TRON founders Ugur Sahin and Özlem Türeci have been named among the Top 20 Translational Researchers (2018) for the 2nd time by Nature Biotechnology. Nature Biotechnology’s ranking is based on the number of total patents (US and European) awarded, the researcher’s top-cited patent over the past 5 years and
After the Healthcare Hackathon at the University Medical Center Mainz, the next round started on September 2nd and 3rd in Berlin. A total of 24 interdisciplinary teams took part in this relaxed competition to develop technology-based solutions for medical applications and care within the scope of their projects. TRON was also represented by Jonas Ibn-Salem
At the annual meeting of the Association for Cancer Immunotherapy (CIMT) in 2019, six scientists received the CIMT Poster Award. Thomas Rösler, a scientist from TRON, won the prize in the category ‘Therapeutic Vaccination’ for his work ‘Modelling immunogenicity with omics data integration’ (Abstract 37). He presented his algorithm TOPAZ, which defines candidates for cancer
Professor Ugur Sahin erhält den Deutschen Krebspreis 2019 Mainz, 28. Februar 2019 – Univ.-Prof. Dr. Ugur Sahin hat den Deutschen Krebspreis 2019 erhalten – eine der angesehensten Auszeichnungen in der Krebsmedizin in Deutschland. Prof. Sahin erhält den Preis in der Kategorie Transferforschung für seine wegweisenden Arbeiten zu individualisierten Krebsimmuntherapien, insbesondere für die Entwicklung und klinische
Official foundation ceremony of HI-TRON Mainz Mainz, February 14, 2019 – The new Helmholtz Institute for Translational Oncology (HI-TRON Mainz) is to become one of the world’s leading centers for personalized cancer immunotherapy. This is the ambitious goal of the cooperation partners German Cancer Research Center (DKFZ) and the Research Institute Translational Oncology (TRON gGmbH)
Mainz, January 31, 2019 – TRON celebrates young talent TRON is sponsoring two scholarships in the Deutschlandstipendium 2018/2019 of the Johannes Gutenberg University Mainz, thereby supporting two young medical students as part of this Federal Ministry of Education and Research program. On January 31st, the festive dinner for Deutschlandstipendium sponsors and scholarship holders took place
Mainz, February 5, 2019 – TRON is thrilled to announce a review published in Annual Review of Medicine authored by Ugur Sahin. In this overview article targeting the medical community, Prof. Sahin defines the cancer mutanome and why this is a valuable source of potential vaccines targets in oncology. The review goes on to describe
Mainz, December, 2018 – TRON is proud to have taken part in the research that lead to this publication in OncoImmunology. This publication – in collaboration with scientists from BioNTech, DKFZ, JPT, and the University Medicine Mainz – points to hurdles on our way to highly personalized cancer immunotherapy. The research group investigated neoepitope-specific CD8+